Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q3 2024 · 10-Q
Revenue$4.35M$4.35M+62.8% vs Q3 2023 Net Income-$1.06M-$1.06MN/M vs Q3 2023 EPS, diluted—
Gross Profit$1,722,000+20.0% Operating Income-$1,061,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,620,000N/M Margins · derivedGross margin39.6%−14.1 pt vs Q3 2023
Operating margin-24.4%+33.1 pt vs Q3 2023
Net margin-24.4%+32.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end